227 related articles for article (PubMed ID: 32702530)
1. Engineering of monosized lipid-coated mesoporous silica nanoparticles for CRISPR delivery.
Noureddine A; Maestas-Olguin A; Saada EA; LaBauve AE; Agola JO; Baty KE; Howard T; Sabo JK; Espinoza CRS; Doudna JA; Schoeniger JS; Butler KS; Negrete OA; Brinker CJ; Serda RE
Acta Biomater; 2020 Sep; 114():358-368. PubMed ID: 32702530
[TBL] [Abstract][Full Text] [Related]
2. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW
ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289
[TBL] [Abstract][Full Text] [Related]
3. Lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition.
Suzuki Y; Onuma H; Sato R; Sato Y; Hashiba A; Maeki M; Tokeshi M; Kayesh MEH; Kohara M; Tsukiyama-Kohara K; Harashima H
J Control Release; 2021 Feb; 330():61-71. PubMed ID: 33333121
[TBL] [Abstract][Full Text] [Related]
4. Virus-like nanoparticle as a co-delivery system to enhance efficacy of CRISPR/Cas9-based cancer immunotherapy.
Liu Q; Wang C; Zheng Y; Zhao Y; Wang Y; Hao J; Zhao X; Yi K; Shi L; Kang C; Liu Y
Biomaterials; 2020 Nov; 258():120275. PubMed ID: 32798741
[TBL] [Abstract][Full Text] [Related]
5. Charge-Selective Delivery of Proteins Using Mesoporous Silica Nanoparticles Fused with Lipid Bilayers.
Shi H; Liu S; Cheng J; Yuan S; Yang Y; Fang T; Cao K; Wei K; Zhang Q; Liu Y
ACS Appl Mater Interfaces; 2019 Jan; 11(4):3645-3653. PubMed ID: 30609348
[TBL] [Abstract][Full Text] [Related]
6. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel.
Wang D; Huang J; Wang X; Yu Y; Zhang H; Chen Y; Liu J; Sun Z; Zou H; Sun D; Zhou G; Zhang G; Lu Y; Zhong Y
Biomaterials; 2013 Oct; 34(31):7662-73. PubMed ID: 23859657
[TBL] [Abstract][Full Text] [Related]
7. TAxI-peptide targeted Cas12a ribonuclease protein nanoformulations increase genome editing in hippocampal neurons.
Sellers DL; Lee K; Murthy N; Pun SH
J Control Release; 2023 Feb; 354():188-195. PubMed ID: 36596342
[TBL] [Abstract][Full Text] [Related]
8. Lipid-coated mesoporous silica nanoparticles for anti-viral applications via delivery of CRISPR-Cas9 ribonucleoproteins.
LaBauve AE; Saada EA; Jones IKA; Mosesso R; Noureddine A; Techel J; Gomez A; Collette N; Sherman MB; Serda RE; Butler KS; Brinker CJ; Schoeniger JS; Sasaki D; Negrete OA
Sci Rep; 2023 Apr; 13(1):6873. PubMed ID: 37105997
[TBL] [Abstract][Full Text] [Related]
9. Recognizing CRISPR as the new age disease-modifying drug: Strategies to bioengineer CRISPR/Cas for direct in vivo delivery.
Thevendran R; Maheswaran S
Biotechnol J; 2023 Sep; 18(9):e2300077. PubMed ID: 37179485
[TBL] [Abstract][Full Text] [Related]
10. In vivo targeted delivery of nucleic acids and CRISPR genome editors enabled by GSH-responsive silica nanoparticles.
Wang Y; Shahi PK; Wang X; Xie R; Zhao Y; Wu M; Roge S; Pattnaik BR; Gong S
J Control Release; 2021 Aug; 336():296-309. PubMed ID: 34174352
[TBL] [Abstract][Full Text] [Related]
11. Exosome/Liposome-like Nanoparticles: New Carriers for CRISPR Genome Editing in Plants.
Alghuthaymi MA; Ahmad A; Khan Z; Khan SH; Ahmed FK; Faiz S; Nepovimova E; Kuča K; Abd-Elsalam KA
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299081
[TBL] [Abstract][Full Text] [Related]
12. [Genome editing in plants directed by CRISPR/Cas ribonucleoprotein complexes].
Li X; Shi W; Geng LZ; Xu JP
Yi Chuan; 2020 Jun; 42(6):556-564. PubMed ID: 32694114
[TBL] [Abstract][Full Text] [Related]
13. Mesoporous Silica Nanoparticle-Supported Lipid Bilayers (Protocells) for Active Targeting and Delivery to Individual Leukemia Cells.
Durfee PN; Lin YS; Dunphy DR; Muñiz AJ; Butler KS; Humphrey KR; Lokke AJ; Agola JO; Chou SS; Chen IM; Wharton W; Townson JL; Willman CL; Brinker CJ
ACS Nano; 2016 Sep; 10(9):8325-45. PubMed ID: 27419663
[TBL] [Abstract][Full Text] [Related]
14. A pH-responsive silica-metal-organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries.
Wang Y; Shahi PK; Xie R; Zhang H; Abdeen AA; Yodsanit N; Ma Z; Saha K; Pattnaik BR; Gong S
J Control Release; 2020 Aug; 324():194-203. PubMed ID: 32380204
[TBL] [Abstract][Full Text] [Related]
15. Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing.
Whitley JA; Cai H
J Extracell Vesicles; 2023 Sep; 12(9):e12343. PubMed ID: 37723839
[TBL] [Abstract][Full Text] [Related]
16. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
17. A Versatile Nonviral Delivery System for Multiplex Gene-Editing in the Liver.
Gong J; Wang HX; Lao YH; Hu H; Vatan N; Guo J; Ho TC; Huang D; Li M; Shao D; Leong KW
Adv Mater; 2020 Nov; 32(46):e2003537. PubMed ID: 33053221
[TBL] [Abstract][Full Text] [Related]
18. Different Methods of Delivering CRISPR/Cas9 Into Cells.
Chandrasekaran AP; Song M; Kim KS; Ramakrishna S
Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786
[TBL] [Abstract][Full Text] [Related]
19. Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species.
Wang P
mSphere; 2018 Jun; 3(3):. PubMed ID: 29898980
[No Abstract] [Full Text] [Related]
20. Lipid-Coated Mesoporous Silica Nanoparticles for the Delivery of the ML336 Antiviral to Inhibit Encephalitic Alphavirus Infection.
LaBauve AE; Rinker TE; Noureddine A; Serda RE; Howe JY; Sherman MB; Rasley A; Brinker CJ; Sasaki DY; Negrete OA
Sci Rep; 2018 Sep; 8(1):13990. PubMed ID: 30228359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
